



## BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019

March 7, 2019

ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 7, 2019-- [BioTime, Inc.](#) (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its fourth quarter and full year 2018 financial and operating results on Thursday, March 14<sup>th</sup>, 2019, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, March 14<sup>th</sup>, 2019, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2018 financial results and to provide a business update.

Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the "BioTime Inc. Call". A live webcast of the conference call will be available online in the [Investors](#) section of BioTime's website. A replay of the webcast will be available on BioTime's website for 30 days and a telephone replay will be available through March 21<sup>st</sup>, 2019, by dialing (855) 859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere outside the U.S. and entering conference ID number 1091719.

### About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime's pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime's lead cell replacement product candidate is OpRegen<sup>®</sup>, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime's lead cell delivery clinical program is Renevia<sup>®</sup>, an investigational medical device being developed as an alternative for whole adipose tissue transfer procedures. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit [www.biotimeinc.com](http://www.biotimeinc.com). To receive ongoing BioTime corporate communications, please click on the following link to join the Company's email alert list: <http://news.biotime.com>.



View source version on businesswire.com: <https://www.businesswire.com/news/home/20190307005024/en/>

Source: BioTime, Inc.

### BioTime Inc. IR

Ioana C. Hone  
([ir@biotimeinc.com](mailto:ir@biotimeinc.com))  
(510) 871-4188

### Solebury Trout IR

Gitanjali Jain Ogawa  
([Gogawa@troutgroup.com](mailto:Gogawa@troutgroup.com))  
(646) 378-2949